Inclusion criteria :

          -  Measurable Metastatic triple negative breast cancer (TNBC).

          -  Patients with CA6-positive disease.

          -  Patients received at least 1 prior chemotherapy regimen but no more than 3 for
             advanced/metastatic disease.

          -  Prior anticancer therapy must have contained anthracycline (eg, doxorubicin), if not
             contraindicated, and a taxane (eg, docetaxel, paclitaxel) in an adjuvant/neo-adjuvant
             or metastatic setting.

        Exclusion criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥2.

          -  Patient less than 18 years old.

          -  Pregnant or breast-feeding women.

          -  Patients with reproductive potential who do not agree to use accepted and effective
             method of contraception during the study treatment period and for 6 months following
             discontinuation of study drug.

          -  Wash out period of less than 3 weeks or 5 half-lives from previous antitumor
             chemotherapy, immunotherapy, or any investigational treatment.

          -  History of brain metastasis (other than totally resected or previously irradiated and
             nonprogressive/relapsed), spinal cord compression or carcinomatous meningitis, or new
             evidence of brain leptomeningeal disease.

          -  Prior treatment with eribulin as last prior therapy or prior maytansinoid treatments
             (DM1 or DM4 antibody-drug conjugates [ADCs]).

          -  Known intolerance to infused protein products including other monoclonal antibodies
             and ADCs.

          -  Poor bone marrow reserve and/or poor organ function.

          -  Symptomatic peripheral neuropathy Grade ≥2.

          -  Previous history of chronic corneal diseases (even if asymptomatic) or unresolved
             acute nonrecurrent corneal conditions.

          -  Patients wearing contact lenses who are not willing to stop wearing them for the
             duration of the study.

          -  Medical conditions requiring concomitant administration of strong CYP3A4 inhibitors,
             unless it can be discontinued at least 2 weeks before 1st administration of SAR566658.

          -  Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.